Literature DB >> 3664498

Antibody-directed targeting of liposomes to human cell lines: role of binding and internalization on growth inhibition.

N Berinstein1, K K Matthay, D Papahadjopoulos, R Levy, B I Sikic.   

Abstract

Small unilamellar liposomes containing methotrexate or methotrexate-gamma-aspartate were conjugated to Staphylococcus aureus protein A and were thus able to bind cell-specific immunoglobulins for targeting to malignant human B- and T-cell lines. We were able to demonstrate enhanced protein A liposome uptake and growth inhibition by targeting with an anti-major histocompatibility complex class II antibody recognizing two different B-cell lines. The enhanced growth inhibition was specific for the targeting antibody and amounted to a 2- to 3-fold lowering of the concentration of drug required to inhibit cell growth by 50% as compared to nontargeted liposomes or liposomes targeted with an antibody not recognizing a cell surface antigen. A strong association between enhanced growth inhibition and liposome internalization as assessed by fluorescent-activated cell sorter analysis of carboxyfluorescein containing protein A liposomes was seen. By contrast, specific enhancement of growth inhibition was not seen with several anti-idiotype antibodies or antibodies to T-cell differentiation antigens. Liposome internalization did not occur with these antibodies. Failure of growth inhibition and PA liposome internalization could not be explained by differences in cell binding of the antibody PA liposomes or the degree of protein A binding of the targeting antibody. Although the ability of the targeting antibody to bind to the cell and to protein A are important, these factors alone are not sufficient to guarantee internalization and growth inhibition. Variations in rates of internalization of various cell surface antigen-antibody complexes may account for different protein A liposome mediated cytotoxicities.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3664498

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  3 in total

1.  Modulation of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an immunoliposome targeting transferring receptor.

Authors:  S Suzuki; K Inoue; A Hongoh; Y Hashimoto; Y Yamazoe
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

2.  Nano - drug Delivery of Apoptosis Activator 2 to AGS Cells by Liposomes Conjugated with Anti-TROP2 Antibody.

Authors:  Taghi Naserpour Farivar; Reza Najafipour; Pouran Johari
Journal:  N Am J Med Sci       Date:  2012-11

3.  Cytotoxicity of anti-c-erbB-2 immunoliposomes containing doxorubicin on human cancer cells.

Authors:  S Suzuki; S Uno; Y Fukuda; Y Aoki; T Masuko; Y Hashimoto
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.